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Abstract
Background: Alpha-1 antitrypsin deficiency (AATD) results from mutations in the SERPINA1 gene and classically
presents with early-onset emphysema and liver disease. The most common mutation presenting with clinical
evidence is the Z mutation, while the S mutation is associated with a milder plasma deficiency. AATD is an under-
diagnosed condition and the World Health Organisation recommends targeted detection programmes for AATD in
patients with chronic obstructive pulmonary disease (COPD), non-responsive asthma, cryptogenic liver disease and
first degree relatives of known AATD patients.
Methods: We present data from the first 3,000 individuals screened following ATS/ERS guidelines as part of the
Irish National Targeted Detection Programme (INTDP). We also investigated a DNA collection of 1,100 individuals
randomly sampled from the general population. Serum and DNA was collected from both groups and mutations
in the SERPINA1 gene detected by phenotyping or genotyping.
Results: The Irish National Targeted Detection Programme identified 42 ZZ, 44 SZ, 14 SS, 430 MZ, 263 MS, 20 IX
and 2 rare mutations. Analysis of 1,100 randomly selected individuals identified 113 MS, 46 MZ, 2 SS and 2 SZ
genotypes.
Conclusion: Our findings demonstrate that AATD in Ireland is more prevalent than previously estimated with Z
and S allele frequencies among the highest in the world. Furthermore, our targeted detection programme
enriched the population of those carrying the Z but not the S allele, suggesting the Z allele is more important in
the pathogenesis of those conditions targeted by the detection programme.
Introduction
Alpha-1 antitrypsin (AAT) deficiency is a hereditary dis-
order first reported in the early 1960s when emphysema
was described in patients with low plasma levels of AAT
protein [1]. The condition is associated with substantially
increased risk for the development of pulmonary emphy-
sema by the third or fourth decades of life and is also
associated with risks for development of hepatic disease
[2], cutaneous panniculitis [3], bronchiectasis [4], vasculi-
tis [5], Wegener’s granulomatosis [6], and lung cancer
[7]. AAT deficiency is characterised by misfolding of the
AAT protein and belongs to a class of genetic diseases
termed conformational disorders [8].
The SERPINA1 gene is highly pleiomorphic with over
100 alleles identified to date [9]. Mutations which confer
an increased risk of developing pulmonary emphysema
and/or liver disease are those in which deficiency alleles
are combined in homozygous or heterozygous states,
yielding AAT serum levels below a putative protective
threshold of 11 μM. The most common variants asso-
ciated with disease are the Z (Glu342Lys) and S (Glu264-
Val) mutations, caused by a single amino acid replacement
of glutamic acid at positions 342 and 264 of the polypep-
tide, respectively [8]. The class of SERPINA1 variants
termed “null” mutations lead to a complete absence of
AAT production and while extremely rare, confer a parti-
cularly high risk of emphysema [10].
AATD is an under-diagnosed condition with most
cases misdiagnosed as COPD or non-responsive asthma.
As a result, long delays between presentation of first
symptoms and correct diagnosis are commonplace [11].
* Correspondence: tcarroll@rcsi.ie
1Department of Medicine, Royal College of Surgeons in Ireland Education
and Research Centre, Beaumont Hospital, Dublin 9, Ireland
Full list of author information is available at the end of the article
Carroll et al. Respiratory Research 2011, 12:91
http://respiratory-research.com/content/12/1/91
© 2011 Carroll et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
Guidelines issued by both the World Health Organisa-
tion and the American Thoracic Society/European
Respiratory Society (ATS/ERS) recommend the estab-
lishment of targeted screening programmes for the
detection of patients with AATD [12,13]. Moreover,
while a large number of cohorts have been investigated,
many of these studies were based on screening sympto-
matic patients, and performed on small groups of less
than 500 individuals with accompanying high risk of
error.
Apart from a few notable exceptions, such as a Swedish
neonatal screening study [2], the lack of large population
based studies using random sampling means the true
prevalence of AATD in most European countries remains
unknown. To address the paucity of data relating to
AATD in the Irish setting, we analysed 1,100 individuals
taken at random from the general population. In addi-
tion, we analysed a targeted population of symptomatic
individuals and compared the findings with our general
population to investigate whether targeted detection
increased yield across all deficiency allele groups.
Materials & Methods
Subjects
A total of 3,000 individuals were screened as part of the
Irish National Targeted Detection Programme (INTDP).
The detection programme is ongoing and began in May
2004 supported by funding from the Irish Government.
The criteria for targeted screening were COPD, non-
responsive asthma, cryptogenic liver disease, first degree
relatives of known AATD patients (including ZZ, SZ and
MZ) and individuals with reduced serum AAT levels
according to the joint ATS/ERS guidelines (Figure 1). In
addition, 1,100 individuals were screened from the
Trinity Biobank DNA collection at St. James’s Hospital
Institute of Molecular Medicine, Dublin. The Trinity Bio-
bank is a national buccal swab DNA collection selected at
random from the electoral register.
Quantification of AAT
AAT levels were measured by radial immunodiffusion
(RID) (Siemens) or by nephelometry (Dade-Behring BN
II). It must be noted that discrepancies exist when com-
paring these two methods for serum AAT quantification.
Nephelometric methods can overestimate AAT concentra-
tions due to haemoglobin or lipid interference, while RID-
based methods have been shown to overestimate AAT
concentrations by as much as 35-40% [14] and are less
precise than nephelometric methods with higher coeffi-
cients of variation [15]. Moreover, the lower sensitivity
inherent to the RID method because of the high lower
limit of detection (0.33 g/L) becomes a factor when testing
ZZ individuals with AAT concentrations <0.33 g/L.
Phenotyping
Qualitative detection and characterisation of AAT pheno-
types was carried out using the Hydrasys electrophoresis
platform (Sebia) and the Hydragel 18 A1AT Isofocusing
kit (Sebia)(Figure 2A) [16]. This isoelectric focusing (IEF)
method on agarose gel has an added immunofixation step
which utilises a specific antibody to AAT, rendering it
superior to traditional IEF techniques.
Genotyping
Genotyping was performed on a LightCycler 480
(Roche) with specific primers and probes (Metabion)
designed for the Z and S mutations as described in a
previous publication (Figure 2B) [17].
Data elaboration and statistical analysis
The prevalence and numbers of genotypes in the Irish
population was calculated by applying the Hardy-Weinberg
principle. Frequencies of genotypes and phenotypes were
calculated and a derivative parameter, notably the type and
number of mutations in each database, defined (Z, S, etc.).
Data was analysed by descriptive statistics, percentage dis-
tribution, chi-square tests and methods for calculating
odds ratios (ORs), 95% confidence intervals (95% CIs),
accuracy and other contingency parameters, as appropriate
[18]. Statistical significance was assumed at two-tailed p <
0.05, unless stated otherwise.
Results
Frequency of Z and S alleles in a random sample of the
Irish Population
In the Trinity Biobank collection, 113 MS heterozygotes,
46 MZ heterozygotes, 2 SS homozygotes, and 2 SZ com-
pound heterozygotes were identified (Figure 3A). This
data yields a frequency of 0.0218 for the Z allele and
0.0541 for the S allele in the Irish population. Assuming
Hardy-Weinberg equilibrium and based on a population
of 4.24 million inhabitants (Census of Ireland 2006,
http://www.cso.ie) these allele frequencies yield 2,015 ZZ
Figure 1 Percentage distribution of 3,000 INTDP patients
according to reason for screening.
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individuals, 10,001 SZ individuals and 12,409 SS indivi-
duals (Table 1). Thus, the estimated prevalence of severe
AATD (ZZ homozygotes) in Ireland is 1/2,104. In addi-
tion to ZZ AATD, the estimated prevalence of intermedi-
ate AATD (SZ compound heterozygote) is 1/424, with
this phenotype also at increased risk of lung and possibly
liver disease, while the estimated prevalence of mild
AATD (SS homozygote) is 1/341. Finally, in terms of car-
riers, the calculated Z and S allele frequencies yield
170,832 MZ heterozygotes and 423,947 MS heterozy-
gotes with an estimated prevalence of 1/25 for MZ and
1/10 for MS.
Prevalence of AATD in the Irish National Targeted
Detection Programme
A total of 3,000 individuals screened for AATD as part of
the national targeted detection programme identified 430
MZ heterozygotes, 263 MS heterozygotes, 44 SZ com-
pound heteroygotes, 42 ZZ homozygotes, and 14 SS
homozygotes (Figure 3B), with allele frequencies of
0.0938 for the Z mutation and 0.0518 for the S mutation
in the targeted population. A further 20 individuals with
the I mutation (Arg39Cys), associated with a mild plasma
deficiency [19] similar to the S mutation, were identified
with an allele frequency of 0.0033, as well as two indivi-
duals with extremely rare mutations, V [20], and Zbristol
[21]. Serum AAT levels among the various phenotypic
groups illustrate the relationship between decreasing
AAT levels and increasing risk of disease (Table 2).
Comparison of Z and S allele frequencies
The frequency of the S allele in a random sample from
the general population was similar to that identified in
the targeted population. However, the frequency of the
Z allele was four-fold higher in the targeted population
compared to the general population (Figure 4). The
numbers of Z and S alleles in both populations are pre-
sented in Table 3. The risk of being registered with a
Figure 2 Methods employed for analysis of AAT mutations. (A) Typical isoelectric focusing gel used for identification of AAT phenotype. (B)
Genotyping assay used to identify the Z mutation.
Figure 3 Analysis of AAT mutations in Ireland. (A) 1,100 DNA samples in the Biobank collection were genotyped for the S and Z mutations.
(B) 3,000 Irish individuals were screened as part of the national targeted detection programme following ATS/ERS guidelines.
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specific condition in the INTDP database is 4.6 times
higher in subjects carrying the Z mutation than in other
carriers or non-carriers (OR = 4.64, 95% CI 3.41 - 6.19).
This is most likely due to the increased risk associated
with the Z mutation compared to the S mutation alone
(OR = 4.48, 95% CI 2.88 - 5.92).
Discussion
Our study describes the prevalence of AATD in a ran-
domly selected sample of 1,100 individuals from the
Irish population and in a targeted population, specifi-
cally with regard to the two most common alleles asso-
ciated with AATD, the Z and S mutations. In the
general Irish population the Z mutation occurs at a fre-
quency of 0.0218, while the S mutation occurs at a fre-
quency of 0.0541. This means 1 in 25 Irish individuals
are heterozygous for the Z allele and 1 in 10 are hetero-
zygous for the S allele. More importantly from a clinical
perspective, 1 in 2,104 Irish individuals are ZZ homozy-
gotes, 1 in 424 are SZ compound heterozygotes, and 1
in 341 are SS homozygotes. In comparison, when we
looked at the INTDP population the Z mutation
occurred at a frequency of 0.0938 and the S mutation
occurred at a frequency of 0.0518. This means that 1 in
7 tested were MZ and 1 in 11 tested were MS. Strik-
ingly, 1 in 71 tested were ZZ, 1 in 68 were SZ and 1 in
214 were SS. Taken as a whole, 27.1% of the targeted
population contained at least one AAT mutation.
Comparing data from the two groups investigated, the
allele frequency for Z is over four-fold higher in the tar-
geted population compared to a sample of the general
population. Targeted detection programmes produce a
higher rate of AATD detection although the risk of miss-
ing asymptomatic individuals exists. However, the four-
fold increase in Z frequency observed highlights the
effectiveness of the targeted screening approach as advo-
cated by ATS/ERS as the most cost-effective method of
detection [12]. There is particular emphasis in the
INTDP on aggressive family screening to identify asymp-
tomatic relatives before significant lung damage has
occurred. This increases the rate of detection of deficient
alleles, and in our study 14% of INTDP individuals were
screened because of a deficient first-degree relative.
Nonetheless, the high frequency of the Z allele in the tar-
geted group underlines the role of this mutation in the
pathogenesis of lung and liver disease. In contrast to Z,
the allele frequency for S was not significantly increased
in the targeted population compared to the Biobank
cohort. This finding was not surprising considering the
Table 1 Estimated Prevalence of AAT Genotypes in
Ireland
Genotype Prevalence [%, 95% CI] Numbers in Ireland
MS 1/10 [10.00%, 9.70 - 10.30%] 423,947
MZ 1/25 [4.03%, 3.97 - 4.09%] 170,832
SS 1/341 [0.29%, 0.20 - 0.40%] 12,409
SZ 1/424 [0.24%, 0.23 - 0.25%] 10,001
ZZ 1/2,104 [0.05%, 0.04 - 0.06%] 2,015
Data from the Trinity Biobank presented as prevalence [% of total population,
95% confidence interval (CI)]. These figures are based on an Irish population
of 4.24 million in the Republic of Ireland (www.cso.ie).
Table 2 AAT Deficient Phenotypes and Concentrations in
the INTDP
Phenotype N Mean AAT (g/L +/- SEM) AAT range (g/L)
MV 1 1.28 n/a
MI 12 1.285 +/- 0.095 0.93 - 2.08
MS 263 1.199 +/- 0.021 0.499 - 3.32
MZ 430 0.871 +/- 0.014 0.442 - 4.08
IS 3 1.004 +/- 0.103 0.801 - 1.14
SS 14 0.842 +/- 0.046 0.556 - 1.20
IZ 5 0.605 +/- 0.076 0.333 - 0.801
SZ 44 0.564 +/- 0.021 0.23 - 0.98
Z/Zbristol 1 0.50 n/a
ZZ 42 0.11 +/- 0.012 0.05 - 0.333
AAT deficient phenotypes and AAT concentrations from the first 3,000
individuals screened in the INTDP listed according to increasing risk of
disease. Data presented as mean AAT concentration +/- standard error of the
mean (SEM).
Figure 4 Comparison of S and Z allele frequencies in the
Biobank population and in the INTDP population.
Table 3 Comparison of the Distribution of S and Z Alleles
in the INTDP cohort and the Biobank cohort
Phenotype INTDP Biobank Total
S versus other
S alleles 311 119 430
Other (including Z) 5689 2081 7770
Total alleles 6000 2200 8200
Z versus other (p < 0.001)
Z alleles 563 48 611
Other (including S) 5437 2152 7589
Total alleles 6000 2200 8200
Z versus S (p < 0.001)
Z alleles 563 48 611
S alleles 311 119 430
Total alleles 874 167 1041
Data analysed by chi-square test with Yates correction.
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lack of strong evidence for risk of disease due to the S
mutation. The S allele is associated with a mild plasma
deficiency of AAT as the S AAT protein is less polymero-
genic than Z AAT [19], and the S allele is assumed clini-
cally significant only when co-inherited with Z or other
deficient alleles. For example, the SZ genotype is a signif-
icant risk factor for COPD [22,23]. Evidence also exists of
abnormal liver function as characterised by elevated liver
enzymes in newborn SZ individuals [2] and a possible
risk for liver disease in later life [24,25]. However, a risk
of COPD due to the MS genotype was not found [23].
A previous Irish study investigated the prevalence of
AATD in 111 Irish coeliac patients compared to 250
blood donors and found gene frequencies of 0.008 for Z
and 0.04 for S in the blood donor group [26]. However,
the small sample size and the less accurate isoelectrofo-
cusing method employed may account for the discre-
pancies with our findings. We have previously used the
same phenotyping method and found the MZ phenotype
was often difficult to correctly identify, compared to the
more accurate and reliable Sebia method now used in
our laboratory. Similar to the revised Irish data on
AATD presented here, studies in other countries may
have significantly under-estimated the frequency of the
Z and S mutations due to small sample size and/or
methodological limitations.
Throughout Europe the frequency of the Z and S muta-
tions varies widely between countries, geographic regions,
and ethnic groups. Approximately 3 - 4% of northern
Europeans carry the Z allele and 6% carry the S allele [27].
The highest frequency of the S allele is found in the Iber-
ian Peninsula with a mean gene frequency of 0.0564, sug-
gesting the mutation is likely to have arisen in the region.
Placing our results in a European context, we observe that
the frequency of 0.0541 for the S mutation in Ireland is
among the highest in Europe, and similar to the Iberian
Peninsula. The frequency of the Z variant is highest in
northern and western European countries with a mean
gene frequency of 0.014, peaking in southern Scandinavia
with a gene frequency of >0.02 [28]. Similar to the S allele,
the frequency of 0.0218 for the Z allele in the Irish popula-
tion is also among the highest in Europe. Interestingly, as
the genotyping methods employed to study the Biobank
cohort only identify Z and S alleles it is worth considering
the gene frequencies described may still underestimate
AATD in Ireland. Other more rare SERPINA1 mutations
could also be present in the Biobank cohort, for example,
we identified 22 rare non-Z, non-S mutations in the
INTDP cohort which would be missed by our genotyping
method.
The high prevalence of AATD in Ireland is not without
precedent. Ireland has the highest prevalence of cystic
fibrosis [29,30] and haemochromatosis [31] in Europe, as
well as high frequencies of other genetic diseases [32].
This can be partly explained by the geographical isolation
of an island on the fringes of Western Europe, with the
genetic background of the population remaining largely
undisturbed by the demographic movements that pre-
vailed on mainland Europe. The Z mutation is thought to
have arisen from a single origin 66 generations or 2,000
years ago [33,34], and its high frequency in southern
Scandinavia suggests that the mutation arose in this area
and was subsequently dispersed by migration patterns
such as the Viking colonisation of north-western Europe
between 800 and 1200 AD [35]. The relatively high fre-
quency of the Z allele in the Irish population may repre-
sent a Viking genetic footprint resulting from significant
settlement in Ireland in the period from 800 to 1200 AD
when large towns and urban centres were established by
Viking settlers including modern Dublin, Limerick and
Cork [36]. The long history of emigration from Ireland
would also suggest that populations of Irish descent in
countries such as America, Canada, and Australia contain
high frequencies of the Z mutation (and S mutation) and
may benefit from screening for AATD.
The relatively high frequency of the S mutation could
suggest that the tribes who first settled on Irish shores
may have migrated from the Iberian Peninsula. The S
mutation is older than the Z and is postulated to have
arisen in the north of the Iberian Peninsula and subse-
quently spread throughout Europe during mass migration
[37]. For example, one of the highest reported frequencies
of the S allele in Europe is in the region of Galicia in
north-western Spain [38], and in general high S frequen-
cies are found all along the western Atlantic seaboard [28].
Other genetic similarities have been described that suggest
a shared ancestral heritage among the populations on the
Atlantic façade of Europe, stretching from northern Iberia
to western Scandinavia and dating back to the end of the
last Ice Age [39].
Another intriguing theory postulated to explain the
high prevalence of AATD in European populations is the
Z and S mutations confer a survival advantage on hetero-
zygotes, of particular relevance in the pre-antibiotic era
[40]. Polymers of Z AAT protein have been found in
lung lavage and shown to act as neutrophil chemoattrac-
tants [41], and an enhanced inflammatory response has
been demonstrated in MZ heterozygotes [42]. The pro-
posed hypothesis suggests the Z and S alleles favour the
generation of polymers at sites of inflammation and these
polymers help focus and amplify the host inflammatory
response to eradicate invading infectious organisms.
In summary, the findings of our study have significant
consequences. We show that AATD is more prevalent
than previously estimated in Ireland [28], with over 2,000
ZZ and 10,000 SZ individuals at significantly increased
risk of developing lung and liver disease. A further
170,000 MZ heterozygotes are estimated in the Irish
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population and this group may also be at risk of develop-
ing COPD, particularly in individuals who smoke [43].
Moreover, we reaffirm the importance of the Z allele in
the clinical disorders associated with AATD. The INTDP
enriched the population of those carrying the Z but not
the S allele, suggesting the Z allele is more important in
the pathogenesis of those conditions targeted by the
detection programme.
It is clear from the data presented here that the state-
ment “AATD is not a rare disease but a disease that is
rarely diagnosed” is particularly apt in the Irish setting [44].
The continuing lack of awareness and under-diagnosis of
this condition is alarming considering the high numbers of
individuals at risk due to deficient SERPINA1 mutations.
The advantages of early and accurate diagnosis of AATD
are manifold and include closer observation and manage-
ment of affected individuals, especially regarding pulmon-
ary and liver health; family member testing; aggressive
smoking cessation efforts; consideration of occupational
hazards and environment exposures; and significant eco-
nomic benefits arising from the reduced burden on health-
care providers [11,45].
Conclusion
This study demonstrates that the Z and S allele frequen-
cies in Ireland are among the highest in the world, with
large numbers of individuals at risk of disease due to
AATD in the Irish population. The vast majority of
these individuals remain undetected. The importance of
an early diagnosis of AATD cannot be over-emphasised
as the resulting appropriate medical follow-up and life-
style changes can help prevent or at least postpone the
development of the lung and liver disease associated
with this condition.
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